RT Conference Proceedings
T1 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus ) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial
A1 Mirza, M. R.
A1 Bjorge, L.
A1 Marme, F.
A1 Christensen, R. DePont
A1 Gil-Martin, M.
A1 Auranen, A.
A1 Ataseven, B.
A1 Rubio, M. J.
A1 Salutari, V.
A1 Lund, B.
A1 Runnebaum, I.
A1 Redondo, A.
A1 Lindemann, K.
A1 Trillsch, F.
A1 Barretina Ginesta, M. P.
A1 Roed, H.
A1 Lohndorf, J.
A1 Nyvang, G-B.
A1 Sehouli, J.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/25337
UL https://hdl.handle.net/10668/25337
LA en
DS RISalud
RD Apr 17, 2025